Back to top
more

CryoLife, Inc. (CRY)

(Delayed Data from NYSE)

$31.42 USD

31.42
264,840

-0.08 (-0.25%)

Updated May 3, 2019 04:02 PM ET

After-Market: $31.42 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cryolife (CRY) Earnings Miss, Revenues Top Estimates in Q4

by Zacks Equity Research

Cryolife (CRY) revenues increase year over year across all geographies and major segments.

CryoLife (CRY) Q4 Earnings Lag Estimates

by Zacks Equity Research

CryoLife (CRY) delivered earnings and revenue surprises of -58.33% and 1.04%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

CryoLife (CRY) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

CryoLife (CRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CryoLife (CRY) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

CryoLife (CRY) delivered earnings and revenue surprises of 33.33% and 0.15%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

CryoLife (CRY) Q3 Earnings Preview: What to Expect

by Zacks Equity Research

CryoLife (CRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Medical Instruments Stock Outlook: Long-Term Prospects Bright

by Zacks Equity Research

Research and development in the medical instruments industry is on the rise. FDA's approval of gene therapy for inherited renal disease and Big Data for healthcare set to revolutionize the field.

Looking for a Top Momentum Pick? Why CryoLife (CRY) is a Great Choice

by Zacks Equity Research

Does CryoLife (CRY) have what it takes to be a top stock pick for momentum investors? Let's find out.

    CryoLife (CRY) Q2 Earnings and Revenues Top Estimates

    by Zacks Equity Research

    CryoLife (CRY) delivered earnings and revenue surprises of 42.86% and 9.07%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

      Ryan McQueeney headshot

      Momentum Trading Strategy, Trump Cancels Kim Meeting | Free Lunch

      by Ryan McQueeney

      Ryan McQueeney discusses how stocks are moving in the wake of news that President Trump has cancelled his meeting with North Korean leader Kim Jung Un and later recaps the latest macroeconomic data. On the second half of the show, Ryan is joined by Zacks momentum guru Dave Bartosiak to talk trading strategies in today's market.

        CryoLife (CRY) Stock Gains 9.5% on Impressive Q1 Earnings

        by Zacks Equity Research

        CryoLife's (CRY) shares gain on growth in all product lines along with strong performance in all geographies in Q1.

          Zacks.com featured highlights include: Mattel, Clean Harbors, Live Nation, CryoLife and Archrock

          by Zacks Equity Research

          Zacks.com featured highlights include: Mattel, Clean Harbors, Live Nation, CryoLife and Archrock

            Discard These 5 Toxic Stocks or Sell Short for Profits

            by Zacks Equity Research

            Overpriced toxic stocks are generally susceptible to external shocks and loaded with a high level of debt.

              CryoLife to Buy JOTEC, Preliminary Revenue Result Out for Q3

              by Zacks Equity Research

              CryoLife (CRY) gained access to the $2-billion global market for stent grafts through JOTEC deal.

                C.R. Bard (BCR) Beats Earnings & Revenue Estimates in Q2

                by Zacks Equity Research

                C.R. Bard's (BCR) solid performance in the Vascular, Urology and Surgical Specialties were the key highlights of the second quarter.

                  Tirthankar Chakraborty headshot

                  New Strong Buy Stocks for July 24th

                  by Tirthankar Chakraborty

                  Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

                    DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay

                    by Zacks Equity Research

                    On Jul 12, we issued an updated research report on NY-based DENTSPLY SIRONA Inc. (XRAY) -- a global leader in the design, development, manufacture and marketing of dental consumables and dental laboratory products.

                      McKesson (MCK) Poised on Improving Generic and Brand Market

                      by Zacks Equity Research

                      On Jul 12, we issued an updated research report on San Francisco, CA-based McKesson Corporation (MCK).

                        AmerisourceBergen's PharMEDium Slows Down, Competition Rife

                        by Zacks Equity Research

                        On Jul 10, we issued an updated research report on Chesterbrook, PA-based AmerisourceBergen Corporation (ABC).

                          CryoLife (CRY) Earnings Beat Estimates, Revenues Lag in Q4

                          by Zacks Equity Research

                          CryoLife, Inc. (CRY) posted fourth-quarter 2016 adjusted earnings per share of 12 cents, beating the Zacks Consensus Estimate of 8 cents.

                            CryoLife (CRY) Now a Strong Buy on Solid Estimate Revisions

                            by Zacks Equity Research

                            On Dec 27, CryoLife Inc. (CRY) was upgraded to a Zacks Rank #1 (Strong Buy).

                              5 Profitable Stocks to Buy for Great Returns

                              by Zacks Equity Research

                              Net income ratio gives us the exact profit level of a company and reflects the percentage of net income to total sales revenue.

                                Tirthankar Chakraborty headshot

                                New Strong Buy Stocks for December 16th

                                by Tirthankar Chakraborty

                                Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday

                                  Zacks.com featured highlights: FormFactor, CryoLife, LegacyTexas Financial, Willdan Group and Stamps.com

                                  by Zacks Equity Research

                                  Zacks.com featured highlights: FormFactor, CryoLife, LegacyTexas Financial, Willdan Group and Stamps.com

                                    CryoLife (CRY) Now a Strong Buy: Should You Add the Stock?

                                    by Zacks Equity Research

                                    On Dec 6, Kennesaw, GA-based CryoLife Inc. (CRY) was raised to a Zacks Rank #1 (Strong Buy).

                                      Tirthankar Chakraborty headshot

                                      New Strong Buy Stocks for November 29th

                                      by Tirthankar Chakraborty

                                      Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday